A 12-week study start-up goal had been established by the sponsor of a Phase II multicenter efficacy and safety study on common warts, so sites were activated on a rolling basis to meet the first patient in (FPI) milestone. Working closely with the site teams and principal investigators, IQVIA Biotech adopted an aggressive strategy to increase the rate of enrollment. We not only increased the enrollment rate but beat projected timelines by five weeks.